---
title: "Brain-Computer Interfaces"
description: "Analysis of BCIs as a path to enhanced human intelligence through direct neural interfaces. As of 2025, Neuralink has implanted 7 patients achieving cursor control and gaming, while Synchron's Stentrode and Precision Neuroscience's Layer 7 show promise with minimally invasive approaches. Current bandwidth remains limited to ~50-62 words/minute for speech decoding, orders of magnitude below AI systems. Slow development timeline makes BCIs unlikely to influence TAI outcomes, though they raise important questions about human-AI integration."
sidebar:
  label: "Brain-Computer Interfaces"
  order: 13
quality: 49
lastEdited: "2026-01-28"
importance: 35.5
researchImportance: 76.5
update_frequency: 21
llmSummary: "Comprehensive analysis of BCIs concluding they are irrelevant for TAI timelines (<1% probability of dominance) due to fundamental bandwidth constraints—current best of 62 WPM vs. billions of operations/second for AI systems—and slow biological adaptation timescales measured in months/years. Well-sourced technical review with extensive clinical data (7 Neuralink patients, multiple FDA clearances) but purely descriptive with no actionable implications for AI prioritization work."
ratings:
  novelty: 3.5
  rigor: 6
  actionability: 2
  completeness: 7
clusters: ["ai-safety"]
entityType: intelligence-paradigm
---
import {Mermaid, EntityLink, DataExternalLinks} from '@components/wiki';

<DataExternalLinks pageId="brain-computer-interfaces" />

## Overview

Brain-Computer Interfaces (BCIs) directly connect biological brains to digital systems, potentially enabling cognitive enhancement, faster communication, and eventually human-AI integration. The vision is humans augmented by AI rather than replaced by it. As of early 2026, the field has seen remarkable clinical progress: Neuralink has implanted its N1 device in seven quadriplegic patients who can now control computers with their thoughts, Synchron's endovascular Stentrode achieved positive safety results in its COMMAND trial, and Precision Neuroscience received FDA clearance for its minimally-invasive Layer 7 interface with over 50 patients implanted across six U.S. medical centers.

While BCIs have made significant medical advances, they are **very unlikely to be relevant for TAI timelines** due to slow development, bandwidth limitations, and the vast capability gap with pure AI systems. The highest communication speeds achieved—62 words per minute for speech decoding in BrainGate trials—remain far below what pure AI systems can process, and cognitive enhancement beyond restoring lost function remains speculative with no demonstrated capability.

**Estimated probability of being dominant at transformative intelligence: less than 1%**

## Current Capabilities

<Mermaid chart={`
flowchart TB
    subgraph medical["Medical BCIs (Proven)"]
        cochlear["Cochlear Implants<br/>~1M users"]
        dbs["Deep Brain Stimulation<br/>Parkinson's, depression"]
        retinal["Retinal Implants<br/>Limited vision"]
    end

    subgraph research["Research BCIs"]
        utah["Utah Array<br/>~100 electrodes"]
        neuralink["Neuralink N1<br/>~1000 electrodes"]
        stentrode["Stentrode<br/>Blood vessel-based"]
    end

    subgraph future["Future Visions"]
        wireless["Wireless High-Bandwidth"]
        bidirect["Full Bidirectional"]
        cognitive["Cognitive Enhancement"]
    end

    medical -->|"Decades of use"| proven["Proven safe"]
    research -->|"Early trials"| uncertain["Uncertain efficacy"]
    future -->|"Far future"| speculative["Speculative"]
`} />

### Comparison of Major BCI Approaches (2025)

| Company/System | Electrodes | Approach | Invasiveness | Status | Key Results | Funding/Valuation |
|----------------|------------|----------|--------------|--------|-------------|-------------------|
| **Neuralink N1** | 1,024 (64 threads) | Intracortical (robotic insertion) | High (craniotomy) | Human trials (7 patients as of June 2025) | Cursor control, gaming, CAD software; thread retraction issues in first patient | ≈\$1B valuation |
| **Synchron Stentrode** | 16 | Endovascular (via jugular vein) | Low (no brain surgery) | COMMAND trial complete (6 patients) | No serious adverse events at 12 months; cursor control, Vision Pro integration | \$145M raised |
| **Precision Layer 7** | 1,024 | Epidural (micro-slit insertion) | Low (no craniotomy, reversible) | FDA cleared (March 2025); 50+ patients | First wireless BCI FDA clearance; less than 1% infection rate | ≈\$100M valuation |
| **Blackrock NeuroPort** | 96-128 per array (up to 1,024) | Intracortical (Utah array) | High (craniotomy) | 40+ implantations since 2004 | 35.6% electrode yield over 7+ years; powers BrainGate | \$150M (Tether acquisition) |
| **BrainGate** | 96-128 (Utah arrays) | Intracortical | High | Ongoing trials since 2004 | 62 WPM speech decoding (2023); 20+ years data | Academic consortium |
| **Cochlear implants** | 12-22 | Inner ear stimulation | Medium (surgery) | FDA approved (1984); ≈1M users | Standard of care for severe hearing loss | Multiple manufacturers |
| **Non-invasive EEG** | 64-256 | Scalp electrodes | None | Consumer/research | 50 bits/sec max; noisy signal | Various |

Sources: [Neuralink Updates](https://neuralink.com/updates/), [Synchron COMMAND Study](https://www.clinicaltrialsarena.com/news/synchrons-bci-meets-primary-endpoint-in-feasibility-trial/), [Precision Neuroscience FDA Clearance](https://www.biospace.com/press-releases/precision-neuroscience-receives-fda-clearance-for-high-resolution-cortical-electrode-array), [Blackrock Neurotech](https://blackrockneurotech.com/products/utah-array/)

### BCI Technology Architecture

<Mermaid chart={`
flowchart TD
    subgraph BRAIN["Brain Interface Layer"]
        neurons["Neurons<br/>~86 billion cells"]
        signals["Neural Signals<br/>Action potentials"]
    end

    subgraph HARDWARE["Hardware Layer"]
        invasive["Invasive Electrodes<br/>Utah Array, Neuralink threads"]
        minimally["Minimally Invasive<br/>Stentrode, Layer 7"]
        noninvasive["Non-Invasive<br/>EEG, fNIRS"]
    end

    subgraph PROCESSING["Signal Processing"]
        amplify["Amplification<br/>and Filtering"]
        decode["Neural Decoding<br/>ML algorithms"]
        interpret["Intent Classification<br/>Movement, speech, typing"]
    end

    subgraph OUTPUT["Output Applications"]
        cursor["Cursor Control<br/>~8-15 WPM typing"]
        speech["Speech Synthesis<br/>~62 WPM"]
        prosthetics["Prosthetic Control<br/>Robotic arms"]
        communication["Communication<br/>Locked-in patients"]
    end

    neurons --> signals
    signals --> invasive
    signals --> minimally
    signals --> noninvasive
    invasive --> amplify
    minimally --> amplify
    noninvasive --> amplify
    amplify --> decode
    decode --> interpret
    interpret --> cursor
    interpret --> speech
    interpret --> prosthetics
    interpret --> communication

    style BRAIN fill:#e8f4ea
    style invasive fill:#ffcccc
    style minimally fill:#fff3cc
    style noninvasive fill:#cce5ff
`} />

## Key Properties

| Property | Rating | Assessment |
|----------|--------|------------|
| **White-box Access** | PARTIAL | Can observe some neural signals but interpretation limited |
| **Trainability** | EMERGING | Brain adapts to interfaces over time |
| **Predictability** | LOW | Neural signals highly variable |
| **Modularity** | LOW | Brain regions highly interconnected |
| **Formal Verifiability** | LOW | Cannot verify what brain does with inputs |

## The Bandwidth Problem

The fundamental limitation of BCIs is not the interface technology but the biological constraints of neural processing. The brain's information processing rate imposes hard limits on what any BCI can achieve.

### Human Brain vs. Digital Systems

| System | Information Rate | Bits/Second | Notes |
|--------|------------------|-------------|-------|
| **Human reading** | ≈50 bits/sec | 50 | Well-established baseline |
| **Human speech** | ≈40 bits/sec | 40 | Similar to reading |
| **Non-invasive BCI (SSVEP)** | ≈50 bits/sec | 50 | Record for visual BCIs (2024) |
| **Best invasive BCI typing** | ≈8 WPM | ≈40 | Point-and-click paradigm |
| **Speech decoding BCI** | ≈62 WPM | ≈310 | BrainGate 2023, imagined speech |
| **Theoretical BCI limit** | ≈10 Mbps | 10,000,000 | Perfect recording of all neurons |
| **USB 3.0** | 5 Gbps | 5,000,000,000 | 500,000x theoretical BCI limit |
| **Human sensory input** | ≈10 Mbps | 10,000,000 | Mostly visual system |
| **GPT-4 token processing** | ≈100k tokens/min | ≈8,000,000 | Orders of magnitude higher |

### Communication Speed Progress

| Year | Achievement | Speed | System | Source |
|------|-------------|-------|--------|--------|
| 2017 | Point-and-click typing | 8 WPM | BrainGate (Utah array) | [eLife](https://elifesciences.org/articles/18554) |
| 2021 | Imagined handwriting | 18 WPM | BrainGate | Stanford/HHMI |
| 2023 | Speech decoding | 62 WPM | BrainGate | [Nature](https://www.nature.com/articles/s41586-023-06377-x) |
| 2024 | Flexible typing interface | ≈15 WPM | BrainGate | NEJM |
| 2025 | Real-time voice synthesis | N/A | Stanford | [Nature](https://www.nature.com/articles/s41586-024-08380-8) |

### Why This Matters

Even perfect BCIs would be bandwidth-limited by what the brain can process. Adding more electrodes doesn't help if the brain can't integrate the information faster. The [Columbia BISC system](https://www.nature.com/articles/s41928-024-01323-9) announced in late 2025 features 65,536 electrodes and 1,024 channels—but translating more neural data into faster cognition remains the bottleneck.

**The core constraint**: Neurons fire at a maximum of ~1,000 Hz, and meaningful cognitive operations require coordinated activity across billions of neurons. Even with perfect signal capture, the brain's internal processing speed limits useful bandwidth to roughly human sensory input rates (~10 Mbps at best).

```
Current: BCI ≈ Human typing speed (8-62 WPM)
Best case: BCI ≈ Human sensory bandwidth (~10 Mbps)
AI systems: Already >> human sensory bandwidth (billions of ops/sec)
```

## Research Landscape

### Key Organizations and Status (2025)

| Organization | Approach | Electrodes | Status | Key Milestones | Partnerships |
|--------------|----------|------------|--------|----------------|--------------|
| **Neuralink** | Intracortical threads | 1,024 | 7 patients (June 2025) | First human implant Jan 2024; gaming, CAD software achieved | N/A (vertically integrated) |
| **Synchron** | Endovascular Stentrode | 16 | COMMAND trial complete | No serious adverse events at 12 months; Apple Vision Pro control | Gates Ventures, Bezos |
| **Precision Neuroscience** | Epidural (Layer 7) | 1,024 | FDA cleared; 50+ patients | First wireless BCI FDA clearance (March 2025) | Medtronic, Mount Sinai, Penn |
| **Blackrock Neurotech** | Utah array (NeuroPort) | 96-1,024 | 40+ implantations | Powers BrainGate; MoveAgain FDA Breakthrough | Tether (\$100M investment) |
| **BrainGate** | Utah array research | 96-128 | Ongoing since 2004 | 62 WPM speech decoding; 20 years data | Brown, Stanford, MGH |
| **Kernel** | Non-invasive (Flow) | N/A | Research/commercial | Helmet-based fNIRS | Flow Neuroscience |
| **Meta** | Non-invasive neural | N/A | Research | EMG wristband for AR/VR | CTRL-labs acquisition |

### Neuralink PRIME Study Progress

| Milestone | Date | Details | Outcome |
|-----------|------|---------|---------|
| FDA Breakthrough designation | 2023 | High-bandwidth implant for paralysis | Accelerated review pathway |
| First human implant (Patient 1) | January 29, 2024 | Noland Arbaugh, quadriplegic | Successful; initial recovery good |
| Thread retraction issue | March 2024 | Some electrode threads detached | Functionality declined, then stabilized |
| Cursor control demonstrated | Q1 2024 | Noland playing chess, browsing web | Hands-free computer control achieved |
| Second implant (Patient 2) | August 2024 | Spinal cord injury patient | Gaming within one month; CAD software |
| Canada expansion | December 2024 | Trials opened in Canada | International expansion |
| Seven patients implanted | June 2025 | All quadriplegia patients | Ongoing monitoring |
| CONVOY Study announced | November 2024 | Testing robotic arm control | Feasibility trials |
| Target for 2025 | End 2025 | 20-30 new participants globally | Expansion to UK, Germany, UAE |

Sources: [Neuralink PRIME Study Updates](https://neuralink.com/updates/prime-study-progress-update/), [ClinicalTrials.gov NCT06429735](https://www.clinicaltrials.gov/study/NCT06429735)

### What BCIs Can Do Today

| Application | Status | Best Performance | System | Notes |
|-------------|--------|------------------|--------|-------|
| **Cursor control** | Working | Reliable for daily use | Neuralink, BrainGate | All major systems achieve this |
| **Point-and-click typing** | Working | ≈8-15 WPM | BrainGate, Neuralink | Functional but slow |
| **Speech decoding** | Working | 62 WPM | BrainGate (2023) | Imagined speech to text |
| **Voice synthesis** | Emerging | Real-time | Stanford (2025) | Instantaneous voice output |
| **Gaming** | Working | Civilization VI, chess | Neuralink | Multiple hours continuous use |
| **Robotic arm control** | Working | 6 degrees of freedom | BrainGate, DARPA | Demonstrated in paralyzed patients |
| **Communication** | Working | Functional for locked-in | Multiple | Standard clinical use case |
| **AR/VR control** | Emerging | Apple Vision Pro | Synchron | Early demonstrations |
| **Cognitive enhancement** | NOT DEMONSTRATED | No evidence | N/A | No system has shown enhancement beyond baseline |

## Safety Implications

BCIs present a complex safety landscape spanning physical, psychological, privacy, and societal concerns. As the technology moves from research to clinical deployment, these risks require careful management.

### BCI-Specific Risks

| Risk Category | Severity | Current Evidence | Mitigation Status |
|---------------|----------|------------------|-------------------|
| **Surgical risks** | MEDIUM | Neuralink thread retraction in Patient 1; Precision less than 1% infection rate | Improving with minimally invasive approaches |
| **Device failure** | MEDIUM | Long-term electrode degradation (BrainGate: 7% decline over 7.6 years) | Ongoing monitoring required |
| **Cybersecurity** | HIGH (potential) | No attacks demonstrated yet; theoretical brain hacking concerns | [EU Council report](https://www.consilium.europa.eu/media/fh4fw3fn/art_braincomputerinterfaces_2024_web.pdf) calls for standards |
| **Neuroprivacy** | HIGH | Neural data can reveal emotions, preferences, unrevealed thoughts | Minnesota enacted criminal penalties (2024) |
| **Psychological** | UNCERTAIN | Identity/agency questions; boundary between self and device | Requires long-term studies |
| **Dependency** | MEDIUM | Patients may rely on functioning device for communication | Redundancy and support protocols needed |
| **Technological senescence** | MEDIUM | Implanted hardware becomes outdated; upgrade challenges | Hardware replacement protocols undefined |

### Emerging Regulatory Framework

| Jurisdiction | Action | Date | Scope |
|--------------|--------|------|-------|
| **Colorado** | Added neurological data to Privacy Act | 2024 | Consumer BCIs |
| **Minnesota** | Criminal penalties for neural data violations | May 2024 | First criminal protections |
| **OECD** | Recommendation on Responsible Innovation in Neurotechnology | 2019, 2023 | International guidelines |
| **UNESCO** | Declaration on Ethics of Neuroscience and Neurotechnology | 2023 | Global ethical framework |
| **FDA** | Breakthrough Device designations | 2020-2025 | Neuralink, Synchron, Precision, Blackrock |

Source: [PLOS Biology - Ethical considerations for BCIs](https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3002899)

### Relevance to AI Safety

| Consideration | Assessment | Explanation |
|---------------|------------|-------------|
| **Human-AI merger** | SPECULATIVE | Could BCIs enable "aligned" human-AI systems? Theoretically appealing but decades away |
| **Oversight capability** | UNLIKELY | Enhanced humans might better oversee AI, but bandwidth limits prevent meaningful speed advantage |
| **Interpretability** | UNCERTAIN | Could neural interfaces help us understand AI? Perhaps bidirectionally, but very early |
| **Timeline irrelevance** | HIGH CONFIDENCE | BCIs too slow to matter for near-term AI risks; 10-20 year timelines vs AI moving in months |
| **Enhancement inequality** | CONCERN | If BCIs enhance cognition, access disparities could create "neuro-elite" class |

## Why Not a Path to TAI

### Fundamental Limitations

| Limitation | Explanation |
|------------|-------------|
| **Bandwidth ceiling** | Brain can only process so fast |
| **Biological constraints** | Neurons fire at ≈1000 Hz max |
| **Integration time** | Takes months/years for brain to adapt |
| **Individual variation** | Each brain is different |
| **AI is faster** | Pure AI improves much more rapidly |

### The Core Problem

```
Even with perfect BCI:
  Human + BCI << Pure AI

BCIs augment humans, but humans are the bottleneck.
AI can be scaled arbitrarily; brains cannot.
```

## Trajectory

### Timeline Estimates with Confidence

| Milestone | Estimated Timeline | Confidence | Key Drivers | Blocking Factors |
|-----------|-------------------|------------|-------------|------------------|
| Reliable cursor control | **Achieved (2024)** | High | Neuralink, BrainGate successes | N/A |
| FDA approval for medical BCIs | 2026-2028 | Medium-High | Synchron, Precision on track | Regulatory caution |
| Consumer non-invasive BCIs | 2027-2032 | Medium | Gaming, productivity applications | User adoption, cost |
| 100+ WPM communication | 2028-2035 | Medium | Algorithm improvements, electrode density | Brain adaptation limits |
| Safe high-bandwidth implants | 2030-2040 | Low-Medium | Next-gen materials, wireless power | Biological rejection, longevity |
| Meaningful cognitive enhancement | 2040+? | Very Low | Unknown breakthroughs needed | No demonstrated path |
| Human-AI integration | Unknown | Speculative | Requires paradigm shift | Fundamental bandwidth limits |

### Market Projections

| Metric | Estimate | Source |
|--------|----------|--------|
| Global BCI market 2024 | \$160B (invasive) | Grand View Research |
| Projected annual growth | 10-17% through 2030 | U.S. GAO |
| Projected market 2045 | greater than \$1.6B | IDTechEx |
| Neuralink valuation | ≈\$1B | Private funding rounds |
| Precision Neuroscience valuation | ≈\$100M | Series C (Dec 2024) |

### Arguments For Relevance

| Argument | Evidence | Strength |
|----------|----------|----------|
| **Neuralink progress** | 7 patients, gaming achieved in months | Moderate - faster than expected but still limited |
| **Medical demand** | ≈5M paralysis patients in US; large market | Strong - clear use case |
| **AI integration** | Could enable human-AI symbiosis | Weak - speculative, no demonstrated path |
| **Long-term importance** | Post-TAI relevance for human agency | Uncertain - depends on AI trajectory |
| **Investment momentum** | \$100M+ recent funding across sector | Moderate - indicates market confidence |

### Arguments Against

| Argument | Evidence | Strength |
|----------|----------|----------|
| **AI is winning** | Pure AI advancing 10-100x faster | Very Strong - fundamental asymmetry |
| **Bandwidth limits** | 62 WPM vs billions of ops/sec for AI | Very Strong - physical constraint |
| **Slow biological timescales** | Brain adaptation takes months/years | Strong - cannot be accelerated |
| **Safety concerns** | Brain surgery risk, public hesitancy | Moderate - improving with minimally invasive |
| **Enhancement not demonstrated** | Zero evidence of cognitive gains beyond baseline | Strong - key claim unproven |

## Comparison with Alternatives

| Approach | Bandwidth | Risk | Timeline | Effectiveness |
|----------|-----------|------|----------|---------------|
| **BCI** | Low | High | Slow | Limited |
| **Education** | Very low | Low | Very slow | Modest |
| **AI tools** | Unlimited | Low | Fast | Very high |
| **AI itself** | N/A | Variable | Very fast | Highest |

## Key Uncertainties

| Uncertainty | Current Assessment | Why It Matters | Resolution Timeline |
|-------------|-------------------|----------------|---------------------|
| **Can bandwidth be dramatically increased?** | Probably not beyond ≈10 Mbps (sensory input limit) | Determines ceiling for BCI capability | 5-10 years for empirical answer |
| **Is partial human-AI integration valuable?** | Unclear; no demonstrations yet | Could provide "good enough" enhancement for some uses | Depends on use case discovery |
| **Will people accept elective implants?** | Low adoption expected; medical necessity drives uptake | Limits market size and development investment | Cultural shift required |
| **Could BCIs help with AI alignment?** | Speculative; neural data could inform value learning | Could provide ground truth for human preferences | 10+ years if ever |
| **Will minimally invasive approaches match invasive?** | Promising; Synchron/Precision showing competitive results | If yes, dramatically expands potential user base | 3-5 years |
| **How long do implants last?** | BrainGate: 7.6 years demonstrated; others unknown | Critical for practical adoption | 10+ years of data needed |

## Historical Timeline

| Year | Milestone | Significance |
|------|-----------|--------------|
| 1998 | First human BCI implant (Kennedy) | Proof of concept |
| 2004 | BrainGate Phase I trial begins | First systematic clinical research |
| 2006 | First BrainGate patient controls cursor | Demonstrated practical control |
| 2012 | Paralyzed woman controls robotic arm (BrainGate) | Complex movement control |
| 2016 | Neuralink founded | Major private investment enters field |
| 2020 | Synchron FDA Breakthrough designation | Endovascular approach validated |
| 2021 | Neuralink monkey plays Pong | Viral demonstration of capability |
| 2021 | Precision Neuroscience founded | Neuralink alumni start competitor |
| 2023 | Neuralink FDA approval for human trials | Regulatory milestone |
| 2023 | BrainGate 62 WPM speech decoding | Speed record for communication |
| 2024 | Neuralink first human implant | Commercial development begins |
| 2024 | Synchron COMMAND trial positive results | Safety demonstrated |
| 2024 | Blackrock \$100M Tether investment | Major funding for Utah array |
| 2025 | Precision Layer 7 FDA clearance | First wireless BCI cleared |
| 2025 | Neuralink reaches 7 patients | Scaling clinical trials |
| 2025 | Columbia BISC 65,536-electrode system | Next-gen hardware announced |

## Sources and Further Reading

### Clinical Trial Data and Company Updates

- **Neuralink PRIME Study**: [Official Updates](https://neuralink.com/updates/) - Progress reports on human trials
- **Synchron COMMAND Trial**: [Clinical Trials Arena](https://www.clinicaltrialsarena.com/news/synchrons-bci-meets-primary-endpoint-in-feasibility-trial/) - 12-month safety and efficacy data
- **Precision Neuroscience FDA Clearance**: [BioSpace](https://www.biospace.com/press-releases/precision-neuroscience-receives-fda-clearance-for-high-resolution-cortical-electrode-array) - Layer 7 regulatory approval
- **BrainGate Long-term Data**: [medRxiv 2025](https://www.medrxiv.org/content/10.1101/2025.07.02.25330310v1) - 20 years of neural recording data
- **Blackrock Neurotech**: [Utah Array Products](https://blackrockneurotech.com/products/utah-array/) - Technical specifications

### Peer-Reviewed Research

- **Brain-X Review (2025)**: [Brain-computer interfaces in 2023-2024](https://onlinelibrary.wiley.com/doi/full/10.1002/brx2.70024) - Comprehensive field review
- **Nature Biomedical Engineering**: [Precision Layer 7 Clinical Outcomes](https://www.auctoresonline.org/article/precision-neurosciences-layer-7-cortical-interface-technical-design-surgical-integration-and-clinical-outcomes)
- **eLife (2017)**: [High performance communication by people with paralysis](https://elifesciences.org/articles/18554) - BrainGate typing speeds
- **Nature Electronics (2025)**: [BISC high-bandwidth neural interface](https://www.nature.com/articles/s41928-024-01323-9) - Columbia 65,536-electrode system

### Ethics and Policy

- **EU Council (2024)**: [From vision to reality: Promises and risks of BCIs](https://www.consilium.europa.eu/media/fh4fw3fn/art_braincomputerinterfaces_2024_web.pdf) - European regulatory perspective
- **PLOS Biology (2024)**: [Ethical considerations for BCIs for cognitive enhancement](https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3002899) - Comprehensive ethics review
- **JMIR Neurotechnology (2024)**: [Invasive BCIs: Critical Assessment](https://neuro.jmir.org/2024/1/e60151) - Future prospects analysis

### Market Analysis

- **IDTechEx**: [Brain Computer Interfaces 2025-2045](https://www.idtechex.com/en/research-report/brain-computer-interfaces/1024) - Industry forecasts
- **Andersen Lab**: [BCIs in 2025: Trials, Progress, and Challenges](https://andersenlab.com/blueprint/bci-challenges-and-opportunities) - Academic perspective
